


**Product Name** : BCI-215  
**Cat. No.** : PC-60691  
**CAS No.** : 1245792-67-9  
**Molecular Formula** : C<sub>22</sub>H<sub>22</sub>BrNO  
**Molecular Weight** : 396.328  
**Target** : Protein Phosphatase/PTP  
**Solubility** : 10 mM in DMSO



## Biological Activity

BCI-215 (BCI215) is a potent, tumor cell-selective **dual specificity MAPK phosphatase (DUSP-MKP)** inhibitor. BCI-215 restores defective MAPK activity caused by overexpression of DUSP1 and DUSP6 in mammalian cells. BCI-215 inhibits cell motility, causes apoptosis but not primary necrosis, and sensitizes cells to lymphokine-activated killer cell activity in MDA-MB-231 human breast cancer cells. BCI-215 induces rapid and sustained phosphorylation of ERK, p38 and JNK, also hyperactivates MKK4/SEK1. BCI-215 causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling.

## References

Kaltenmeier CT, et al. *J Pharmacol Exp Ther.* 2017 Apr;361(1):39-50.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com